Sign In
Buy DNLI
$19.66
+0.310 (+1.60%)
At Close: Jun 03, 2026
Denali Therapeutics Inc. (DNLI) Tops Q2 Earnings and Revenue Estimates
07:42pm, Tuesday, 08'th Aug 2023
Denali Therapeutics Inc. (DNLI) came out with quarterly earnings of $1.30 per share, beating the Zacks Consensus Estimate of a loss of $0.86 per share. This compares to loss of $0.48 per share a year
MPS II And Beyond: Implications Of Denali's Promising Pipeline
12:51am, Sunday, 23'rd Jul 2023
Denali Therapeutics is a promising underdog in the biotech sector, focusing on neurodegenerative diseases, with significant investments in scientific exploration and a robust financial health despite
Cash In on the Longevity Boom: 3 Biotech Stocks to Buy Now
05:13am, Thursday, 29'th Jun 2023
Longevity efforts are forefront of the news cycle today, due in large part to recent coverage of tech billionaire Bryan Johnson's unique strategy to delay aging. This has investors trying to sniff out
Denali (DNLI) Provides Update on Hunter Syndrome Study
05:04pm, Wednesday, 21'st Jun 2023
Denali's (DNLI) early-to-mid-stage study of DNL310 shows a robust reduction in neurofilament light levels for patients with MPS II (Hunter syndrome).
Why Shares of Denali Therapeutics Are Up Monday
04:31pm, Monday, 15'th May 2023
Denali released first-quarter earnings last week. The company focuses on therapies to treat neurodegenerative diseases and has a relatively deep pipeline.
Denali (DNLI) Q1 Earnings Miss Estimates, Pipeline in Focus
02:31pm, Tuesday, 09'th May 2023
Denali (DNLI) delivers a wider Q1 loss while collaboration revenues surpass estimates.
Denali Therapeutics Inc. (DNLI) Reports Q1 Loss, Tops Revenue Estimates
07:02pm, Monday, 08'th May 2023
Denali Therapeutics Inc. (DNLI) came out with a quarterly loss of $0.80 per share versus the Zacks Consensus Estimate of a loss of $0.71. This compares to loss of $0.53 per share a year ago.
Why Is Denali Therapeutics Inc. (DNLI) Down 16% Since Last Earnings Report?
01:00pm, Wednesday, 29'th Mar 2023
Denali Therapeutics Inc. (DNLI) reported earnings 30 days ago. What's next for the stock?
Denali (DNLI) Q4 Earnings Beat Estimates, Pipeline in Focus
10:33am, Tuesday, 28'th Feb 2023
Denali (DNLI) reports better-than-expected results for the fourth quarter and full-year 2022, as it beats both earnings and revenue estimates.
Denali Therapeutics Inc. (DNLI) Reports Q4 Loss, Tops Revenue Estimates
06:49pm, Monday, 27'th Feb 2023
Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of 3.85% and 28.09%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the st
3 More Mid-Cap Biotechs The Street Sees Doubling
08:46am, Wednesday, 22'nd Feb 2023
Over the next 10 to 20 years, some of healthcare's most impactful innovations will come from biotechnology companies. They'll produce medicines based on living organisms that will save and improve the
Denali Therapeutics Announces Presentations on Enzyme Transport Vehicle (ETV) Development Programs for MPS Diseases at the Upcoming WORLDSymposium™
09:01pm, Wednesday, 15'th Feb 2023 GlobeNewswire Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to c
Denali Therapeutics Inc. (DNLI) Surges 5.8%: Is This an Indication of Further Gains?
06:22pm, Friday, 03'rd Feb 2023 Zacks Investment Research
Denali Therapeutics Inc. (DNLI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further pri
Denali Therapeutics Inc. (DNLI) Surges 5.8%: Is This an Indication of Further Gains?
03:03pm, Friday, 03'rd Feb 2023
Denali Therapeutics Inc. (DNLI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further pri
Bristol Myers Squibb (BMY) Q4 Earnings and Revenues Surpass Estimates
01:15pm, Thursday, 02'nd Feb 2023 Zacks Investment Research
Bristol Myers (BMY) delivered earnings and revenue surprises of 6.43% and 2.37%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
